Skip Navigation

MAO-B inhibitors

Important! You should always read carefully the information leaflet that comes with your medication before you start using it. Always check with your doctor or other healthcare professional before altering any of your medications or taking over-the-counter medications as they can interfere with Parkinson’s medications and may have unwanted side effects. Remember also to tell your doctor if you take over-the-counter drugs that can be bought without a prescription.


What you should know about your medication

Each medication has its own particular properties and important considerations to be aware of. Below are some key aspects to think about before you start taking your medication. Detailed information regarding these can be found in the Patient Information Leaflet (PIL):

  • what is it and what is it used for?
  • special warnings and precautions
  • how to take it
  • possible side effects
  • contraindications (when not to use it)
  • interaction with other medication(s)
  • what to do if you forget to take a dose
  • what to do if you take more than you should
  • possible effects on your ability to drive or use machinery
  • safety in pregnancy and breast-feeding
  • how to store.
Parkinson's medication overview
Generic name Brand name ®

MAO-B inhibitors

  • Selegiline
  • Selegiline
  • Rasagiline
  • Eldepryl
  • Zelapar
  • Azilect

MAO-B inhibitors

Azilect® is used for the treatment of Parkinson’s. It can be used together with or without Levodopa (another medicine that is used to treat Parkinson’s).

In Parkinson’s there is a loss of cells that produce dopamine in the brain. Dopamine is a chemical in the brain involved in movement control. Azilect® helps to increase and sustain levels of dopamine in the brain.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Azilect®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Azilect® European Public Assessment Report (EPAR) -  Read report

Eldepryl® is a monoamine oxidase-B inhibitor, and is used in the treatment of Parkinson’s. Eldepryl® may be taken alone in the early stages of your condition, delaying the need for the addition of other medicines. Eldepryl® however can also be used in conjunction with other treatments such as Levodopa to reduce the on-off symptoms or uncontrolled movements you may experience. This happens especially when the effects of the other treatments are wearing-off. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Eldepryl®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Zelapar® contains a medicine selegiline hydrochloride. This belongs to a group of medicines called ‘monoamine oxidase B inhibitors’.

Zelapar® is used to treat Parkinson’s. It can be used with another medicine called Levodopa or on its own.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Zelapar®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Back to top